We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.26%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.91B
AUM Growth
-$2.56B
Cap. Flow
+$5.6B
Cap. Flow %
70.85%
Top 10 Hldgs %
34.65%
Holding
156
New
13
Increased
15
Reduced
59
Closed
23

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$7.7B
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$114M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$76.7M
4
FOLD
Amicus Therapeutics
FOLD
+$76.6M
5
SCPH
scPharmaceuticals
SCPH
+$48.1M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$172M
2
AET
Aetna Inc
AET
+$163M
3
BIIB icon
Biogen
BIIB
+$128M
4
MRK icon
Merck
MRK
+$108M
5
GILD icon
Gilead Sciences
GILD
+$107M

Sector Composition

Rank Sector Weight
1 Healthcare 91.1%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
51
Intellia Therapeutics
NTLA
$1.49B
$44.9M 0.57%
2,337,684
-324,496
-12% -$7.49M
IOVA icon
52
Iovance Biotherapeutics
IOVA
$2.04B
$44.4M 0.56%
5,548,326
-877,300
-14% -$7.04M
SYK icon
53
Stryker
SYK
$134B
$44.3M 0.56%
286,000
-135,000
-32% -$20.6M
KALA icon
54
KALA BIO
KALA
$12.1M
$43.9M 0.56%
951
– –
RDUS
55
DELISTED
Radius Health, Inc.
RDUS
$43.6M 0.55%
1,371,700
+248,900
+22% +$7.81M
RYTM icon
56
Rhythm Pharmaceuticals
RYTM
$7.37B
$43.5M 0.55%
+2,901,295
New +$76.7M
SHPG
57
DELISTED
Shire pic
SHPG
$42.3M 0.53%
272,508
-127,400
-32% -$18.9M
BMY icon
58
Bristol-Myers Squibb
BMY
$130B
$42.2M 0.53%
688,000
-186,700
-21% -$11.7M
AGN.PRA
59
DELISTED
Allergan plc
AGN.PRA
– –
0
– –
SCPH
60
DELISTED
scPharmaceuticals
SCPH
$41.2M 0.52%
+3,409,865
New +$48.1M
GILD icon
61
Gilead Sciences
GILD
$166B
$37.4M 0.47%
521,600
-1,406,400
-73% -$107M
ALPN
62
DELISTED
Alpine Immune Sciences Inc
ALPN
$36.9M 0.47%
3,298,516
– –
PFE icon
63
Pfizer
PFE
$144B
$35.6M 0.45%
1,035,028
-1,556,547
-60% -$53.1M
DVA icon
64
DaVita
DVA
$15.6B
$34.5M 0.44%
+477,400
New +$29.4M
IART icon
65
Integra LifeSciences
IART
$1.41B
$34.1M 0.43%
711,710
-379,200
-35% -$18.6M
DERM
66
DELISTED
Dermira, Inc.
DERM
$32.8M 0.42%
1,181,168
-237,705
-17% -$6.3M
EHTH icon
67
eHealth
EHTH
$43.5M
$31.9M 0.4%
1,834,700
– –
ARGX icon
68
argenx
ARGX
$55B
$31.6M 0.4%
500,000
– –
EVHC
69
DELISTED
Envision Healthcare Holdings Inc
EVHC
$30.3M 0.38%
875,400
+434,700
+99% +$15.2M
DCPH
70
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$26.7M 0.34%
1,176,070
+781,800
+198% +$15.3M
ACAD icon
71
Acadia Pharmaceuticals
ACAD
$4.43B
$25.6M 0.32%
+849,100
New +$27.2M
OBSV
72
DELISTED
ObsEva SA Ordinary Shares
OBSV
$25.4M 0.32%
2,605,531
– –
XFOR icon
73
X4 Pharmaceuticals
XFOR
$376M
$23.8M 0.3%
+10,383
New +$26.3M
ACHN
74
DELISTED
Achillion Pharmaceuticals
ACHN
$23.5M 0.3%
8,170,973
-4,891,927
-37% -$17.8M
NBRV
75
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$23.4M 0.3%
15,678
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2017 Portfolio in Review

As of Q4 2017, OrbiMed held 156 positions worth $7.91B, down 24% from $10.5B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed deployed $5.6B of net new capital in Q4 2017, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $163M trimmed.

  • OrbiMed's largest Q4 2017 buy was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.
  • OrbiMed added most to Loxo Oncology, Inc in Q4 2017, an estimated $7.7B increase.
  • OrbiMed's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $163M.
  • OrbiMed fully exited Incyte in Q4 2017, selling an estimated $172M.
  • OrbiMed's ten largest holdings make up 35% of its $7.91B portfolio in Q4 2017.
  • OrbiMed opened 13 new positions and closed 23 in Q4 2017.
  • OrbiMed's portfolio value fell 24% quarter-over-quarter to $7.91B.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.